Compare · FONR vs TMDX
FONR vs TMDX
Side-by-side comparison of Fonar Corporation (FONR) and TransMedics Group Inc. (TMDX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both FONR and TMDX operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- TMDX is the larger of the two at $3.25B, about 25.9x FONR ($125.1M).
- Over the past year, FONR is up 23.7% and TMDX is down 18.7% - FONR leads by 42.4 points.
- TMDX has hit the wire 5 times in the past 4 weeks while FONR has been quiet.
- TMDX has more recent analyst coverage (19 ratings vs 0 for FONR).
- Company
- Fonar Corporation
- TransMedics Group Inc.
- Price
- -
- -
- Market cap
- $125.1M
- $3.25B
- 1M return
- +0.90%
- +25.93%
- 1Y return
- +23.70%
- -18.71%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1981
- 2019
- News (4w)
- 0
- 5
- Recent ratings
- 0
- 19
Fonar Corporation
FONAR Corporation, together with its subsidiaries, engages in the research, development, production, and marketing of magnetic resonance imaging (MRI) scanners for the detection and diagnosis of human diseases in the United States. The company operates through two segments, Medical Equipment segment, and Physician Management and Diagnostic services segment. It provides Upright MRI scanner that allows patients to be scanned in weight-bearing conditions, such as standing, sitting, bending, or lying down. The company offers non-medical management, including administrative services, billing and collection services, credentialing services, contract negotiations, compliance consulting, purchasing IT services, hiring, conducting interviews, training, supervision and management of non-medical personnel, storage of medical records, office space, equipment, repair maintenance services, accounting, assistance with compliance matters and the development and implementation of practice growth and marketing strategies. The company owns and operates 5 diagnostic imaging facilities in Florida; and manages 39 MRI scanning facilities, including 25 facilities located in New York and 14 situated in Florida. It markets its scanners to private diagnostic imaging centers and hospitals. The company was incorporated in 1978 and is based in Melville, New York.
TransMedics Group Inc.
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG, a portable perfusion, ventilation, and monitoring system that maintains the organ at a near-physiologic state allowing physicians to assess and improve the condition of lungs between the donor and recipient sites; OCS Heart, a portable, warm perfusion, and monitoring system designed to keep a donor heart at a human-like, metabolically active state; and OCS Liver, a system that is evaluated in clinical trials for utilized and unutilized donor livers. TransMedics Group, Inc. was founded in 1998 and is headquartered in Andover, Massachusetts.
Latest FONR
- Amendment: SEC Form SCHEDULE 13G/A filed by Fonar Corporation
- SEC Form 15-12G filed by Fonar Corporation
- SEC Form 4 filed by Director Chan Claudette
- New insider Chan Claudette claimed ownership of 106 units of FONAR CORPORATION COMMON STOCK (SEC Form 3)
- SEC Form 4 filed by Director Lehman Ronald G.
- Director Lehman Ronald G. was granted 4,330 units of FONAR CORPORATION COMMON STOCK (SEC Form 4)
- SEC Form 3 filed by new insider Lehman Ronald G.
- SEC Form 4 filed by Director Carrino Robert M.
- SEC Form 3 filed by new insider Carrino Robert M.
- SEC Form 4 filed by Director Maher Jessica
Latest TMDX
- Director Tobin James R gifted 18,000 shares (SEC Form 4)
- SEC Form 10-Q filed by TransMedics Group Inc.
- TransMedics Group Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- TransMedics Reports Second Quarter 2026 Financial Results
- TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- TransMedics to Present at the Canaccord Genuity 46th Annual Growth Conference
- UBS initiated coverage on TransMedics Group with a new price target
- TransMedics to Report Second Quarter 2026 Financial Results on August 4, 2026
- Officer Corcoran Nicholas was granted 11,727 shares, increasing direct ownership by 39% to 41,558 units (SEC Form 4)
- Chief Financial Officer Hernandez Gerardo was granted 17,246 shares, increasing direct ownership by 117% to 31,935 units (SEC Form 4)